Santarus, Inc. (NASDAQ:SNTS)
CAPS Rating:
A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
RSS Headlines
Fool UK
Recs
FDA will not approve... Inside info boys!!!
Will lose 20-25 pct easily, FDA will need more data